Five of six claims (Claims 1–4, 6) have no detectable scientific support in PubMed, clinical trial registries, or peer-reviewed literature. Claim 5 (MOTS-c and mitochondrial stress) shows genuine early clinical interest, with an active human trial measuring MOTS-c during oxidative stress conditions and internal reference to preclinical cardiac stress models; however, this represents exploratory research rather than established efficacy. Across all claims, no specific studies are cited by the creator, and no human clinical evidence demonstrates any of these proposed benefits for a product called 'motsy' or 'MOTS-c.'
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
The answer might surprise you…
Video transcriptshow
Everyone's telling you to cycle motocy, but that's only half the story. What if I told you that motocy, unlike other peps, doesn't bind to your receptors? So it's actually something you can do longer than a cycle. You can run it year round. In this video I'm gonna be explaining why that is and how long you can actually take it for. So make sure you save this video. Make sure you follow me. There's…
Show full video transcript
a free Pep discord in my bio. Think of most peptides like a doorbell. You press the doorbell, the signal goes through, and if you press that doorbell enough times, the doorbell eventually becomes less responsive. That is called receptor desensitization, and that's what most PEPs do. And that's also why most PEPs are cycled. But motsy is different. Instead of acting like someone constantly ringing the doorbell, motsy acts more like a manager that walks into a factory and tells and helps the workers to do their jobs better. Cells are the factory, mitochondria is the power plants inside of that factory. Mod C helps your mitochondria become more efficient, burn fuel better, handle stress better, and improve metabolic flexibility. Rather than constantly forcing a receptor to activate. It actually changes how the cell behaves. And that's why a lot of research suggests you can take this long term. So what I recommend doing is doing your initial cycle. Um, what I did for mine was I did 5 MG's 3 times a Week for a total of 8 weeks. If you're not good on math there, that is 15 mg's a week times 8, making 120 mg's. And then after that, I've just done 300 to 500 MCG's every day. I've had no diminishing returns, and my energy levels and all of the good things I was experiencing on it still feel as though they did when I was on cycle. But it is important to remember, research is limited on this, but that is exactly what I've done. That's what work for me. And I know a lot of people that actually are running this long term. So do what you want. If you're loving the effects on it, by all means, keep going. Don't stop. Um, if you have any more questions or need any help, put them in the comments. If you need a good source for any of the things I talk about, especially motsy links in my bio. Hope that up.
Show lessClaim breakdown
6 claims“motocy, unlike other peps, doesn't bind to your receptors.”
No published literature, clinical trials, or PubMed abstracts were found describing a receptor-binding mechanism specific to any peptide called 'motocy' or addressing non-receptor binding as a distinguishing feature.
“receptor desensitization is what most PEPs do.”
The clinical trials identified (NAC + behavioral therapy, oxytocin receptor desensitization in myometrium, transplant desensitization protocols) are unrelated to bioregulatory peptides or their general mechanisms of action. No PubMed literature supports the claim that 'most peptides' operate via receptor desensitization.
Supporting studies
“Motsy helps your mitochondria become more efficient.”
No published studies, clinical trials, or PubMed abstracts were found linking 'motsy' (or MOTS-c) to mitochondrial efficiency improvements as a standalone claim.
“Motsy helps your mitochondria burn fuel better.”
No published studies, clinical trials, or PubMed abstracts were found specifically testing whether MOTS-c improves mitochondrial fuel-burning capacity in humans or animals.
“Motsy helps your mitochondria handle stress better.”
A registered human clinical trial (NCT07678073, recruiting) is directly measuring MOTS-c levels in the context of oxidative stress and ferroptosis during renal transplantation, supporting the conceptual direction that MOTS-c relates to mitochondrial stress handling. Internal PeptIQ knowledge also references MOTS-c cardiac ischemia-reperfusion injury studies (2026 rat-heart model) and a Phase 2a prediabetes trial, indicating preclinical and early clinical investigation into stress-response pathways.
“Motsy helps your mitochondria improve metabolic flexibility.”
No published studies, clinical trials, or PubMed abstracts were found specifically testing MOTS-c's effects on metabolic flexibility in humans or animals.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error